SCHEMBL4473023

SCHEMBL4473023

COc1cc[c]c2nc(C(N)=O)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.41
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALOX15 P16050 1/20 0.36
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
IKBKB O14920 1/20 0.35
GRM2 Q14416 2/20 0.34
PDE3B Q13370 1/20 0.34
SIRT6 Q8N6T7 1/20 0.34
GPR35 Q9HC97 1/20 0.33
KDR P35968 3/20 0.33
IRAK4 Q9NWZ3 2/20 0.33
AURKA O14965 2/20 0.33
MET P08581 2/20 0.33
TEK Q02763 2/20 0.33
AURKB Q96GD4 2/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050408 0.78 PIM1 (0.33) NNMTKDM4EIKBKBGRM2ALDH1A1
SCHEMBL4484391 0.77 GRM2 (0.35) NNMTGRM2PIM1
SCHEMBL11973236 0.77 PIM1 (0.38) NNMTIKBKBGRM2SIRT6PIM1
SCHEMBL10994055 0.74 CYP1A2 (0.38) NNMTKDM4EALDH1A1HPGD
SCHEMBL11973850 0.73 KMT2A (0.40) GRM2PIM1
SCHEMBL5447337 0.70 GRM2 (0.35) NNMTKDM4EIKBKBGRM2PIM1
SCHEMBL5708926 0.69 NNMT (0.50) NNMTKDM4EL3MBTL1ALOX15PDE4A
SCHEMBL19329369 0.68 PIM1 (0.49) NNMTKDM4ELCKALDH1A1GAA
SCHEMBL3341422 0.68 GRM2 (0.41) IKBKBGRM2PIM1
SCHEMBL4482433 0.68 APP (0.43) NNMTKDM4EGRM2APPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A NNMT 372/4885KDM4E 1483/4885L3MBTL1 3019/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A NNMT 372/4885KDM4E 1483/4885L3MBTL1 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.